title: Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design.
abstract: Progression of lipid rich necrotic core elements of atherosclerotic vulnerable plaque (VP) or its rupture leads to a majority of cardiovascular events. Endothelial progenitor cells (EPC) contribute to vascular healing and play a crucial role in repair following ischemic injury primarily by endothelialization of VP and neovascularization of ischemic myocardium. We present the rationale and design of the Plaque Regression and Progenitor Cell Mobilization with Intensive Lipid Elimination Regimen or the PREMIER Trial, which is designed to address the question for the very first time whether a highly intensive low-density lipoprotein (LDL)-lowering therapy with LDL-apheresis could lead to a more rapid and detectable reduction in coronary atheroma volume, along with a robust mobilization of EPC compared to standard statin therapy, in patients selected for percutaneous coronary intervention for an acute coronary syndrome.
authors.affiliation: Department of Medicine, VA North Texas Health Care System, Dallas, TX; Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Subhash
authors.initials: S
authors.lastname: Banerjee
authors.forename: Mazen
authors.initials: M
authors.lastname: Abu Fadel
authors.forename: Ravi
authors.initials: R
authors.lastname: Sarode
authors.forename: Lance
authors.initials: L
authors.lastname: Terada
authors.forename: Thomas
authors.initials: T
authors.lastname: Moritz
authors.forename: Ping
authors.initials: P
authors.lastname: Luo
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Hastings
authors.forename: Emmanouil S
authors.initials: ES
authors.lastname: Brilakis
authors.forename: Domenic
authors.initials: D
authors.lastname: Reda
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D001781:Blood Component Removal; D008078:Cholesterol, LDL / Q000097:blood / Q000302:isolation & purification*; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging; D066026:Endothelial Progenitor Cells / Q000502:physiology; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D058226:Plaque, Atherosclerotic / Q000188:drug therapy*; D012107:Research Design; D018084:Ultrasonography, Interventional
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: atherosclerosis; endothelial progenitor cell (EPC); hyperlipidemia; low-density lipoprotein (LDL) apheresis